2026-07-20

ACW — Xanamem depression trial published in British J Psychiatry

Xanamem demonstrated statistically significant antidepressant activity in treatment-resistant MDD with cognitive impairment in a Phase 2a proof-of-concept, with benefit lagging (Week 10 peak) but consistent with cortisol-related mechanism; no cognition benefit observed, though drug was safe and well-tolerated. Publication in a leading psychiatry journal validates the mechanism and supports continued development pending funding and partnerships, with topline Alzheimer's results expected November 2026.

💰 MADRS improvement vs placebo: 2.7 points at Week 10 (p < 0.05) · MADRS improvement in SSRI subgroup: 4.2 points (p < 0.05) · Trial enrollment: 165 participants with difficult-to-treat MDD + cognitive impairment · Publication venue: British Journal of Psychiatry (peer-reviewed)

Materiality: Peer-reviewed publication de-risks mechanism of action and indicators clinical proof-of-concept in a difficult indication; material for late-stage biotech but insufficient data on cash burn or pipeline value weighting to quantify against $152m market cap.

Priced in? Stock +20% over 20d into announcement, -5% over 5d; result aligns with prior Phase 2a data announced August 2024, so journal publication is validation rather than new efficacy indicator; institutional buying ($5k) dwarfed by retail ($120k) suggesting mixed interpretation.

high-confidence read, materiality quantified

DRE · $74M — 12 Mineralised Corridors Identified and Growing

DRE has identified 12 gold mineralised corridors totalling ~40 km strike across Illaara using systematic air-core drilling on one of the Yilgarn's last underexplored greenstone belts, with results bolstered by strong orogenic pathfinders but grades to date remain sub-economic (0.2–1.4 g/t). Only 10% of the belt tested; follow-up infill drilling planned August 2026 could materially narrow focus to higher-priority targets.

💰 Mineralised corridors identified: 12 distinct (40 km total strike) · Program progress: 380 of ~500 holes completed (76%) · Area tested: ~10% of Illaara greenstone belt · Best intercept (Black Oak): 21m @ 0.3 g/t Au, incl. 3m @ 1.1 g/t Au

Materiality: Insufficient data on burn rate or cash reserves; raising cannot be quantified. Exploratory update on a $74m market-cap junior—material in narrative terms (40 km of corridors on underexplored ground), but no resource or commercial milestone announced.

Priced in? No run-up in past 20 or 5 days; market largely flat into announcement, suggesting new information not yet reflected.

🏔 ~200km near RMS.AX ($5.4B — 72.73× subject cap) · ~5km near NST.AX ($27.1B major in district) · ~15km near EVN.AX ($21.1B major in district)

deep-dive context available

EVR — EVR to Undertake Rights Issue and Change of Management

EVR is raising A$1.52m to fund proof-of-concept commissioning at its Tecomatlán antimony plant and offtake development, signalling transition from exploration to production pathway. Management change (MD/CEO out, Shane Menere as Exec Chairman, Miguel Barahona as Interim CEO) underscores operational refocus with experienced mining executives.

💰 Rights Issue Size: A$1.52m · Subscription Ratio: 1 new share per 10 held · Issue Price: A$0.005 per share · Underwritten Amount: A$1.0m (66% of total)

Materiality: Raise ~10% of current market cap; $1m underwriting by board-linked Indian Ocean Securities demonstrates director backing; capital targeted at near-term antimony production de-risking rather than exploration.

Priced in? Stock down 29% over 20d and 17% over 5d into announcement; deterioration suggests market anticipated capital raise but management transition may be partial surprise.

high-confidence read, materiality quantified